Gene therapy breakthrough? first human trial launches for rare brain disorder

NCT ID NCT07135050

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new gene therapy called MZ-1866 for children and adults with Pitt Hopkins Syndrome, a rare genetic condition that affects development and breathing. The therapy is given as a single injection into the fluid around the brain. The main goal is to see if it is safe and tolerable, with 12 participants being closely monitored for side effects and changes in health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MZ-1866 (a gene therapy delivered via injection into the brain's fluid spaces)
What this could lead to
If successful, this could point toward a treatment that controls or reduces the symptoms of Pitt Hopkins Syndrome, a rare genetic disorder.
What could go wrong
This is a very early, first-in-human trial with only 12 participants, so safety and effectiveness are not yet known. Gene therapies can have unpredictable side effects, and the approach may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PITT HOPKINS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Children's Hospital Colorado

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Rush University Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

  • Sheba Medical Center

    RECRUITING

    Tel Litwinsky, Israel

  • UCSF Benioff Children's Hospital Oakland

    RECRUITING

    Oakland, California, 94609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.